A Practical Approach to Interpreting Circulating Tumor DNA in the Management of Gastrointestinal Cancers

Clinical Chemistry, Journal Year: 2024, Volume and Issue: 70(1), P. 49 - 59

Published: Jan. 1, 2024

Abstract Background There is accumulating evidence supporting the clinical use of circulating tumor DNA (ctDNA) in solid tumors, especially different types gastrointestinal cancer. As such, appraisal current and potential utility ctDNA needed to guide clinicians decision-making facilitate its general applicability. Content In this review, we firstly discuss considerations surrounding specimen collection, processing, storage, analysis, which affect reporting interpretation results. Secondly, evaluate a selection studies on colorectal, esophago-gastric, pancreatic cancer determine level for disease screening, detection molecular residual (MRD) recurrence during surveillance, assessment therapy response, guiding targeted therapy. Lastly, highlight limitations future directions. Summary Current promising but varies depending specific role type. Larger prospective trials are validate aspects utility, standardization collection protocols, analytical assays, guidelines should be considered wider

Language: Английский

---

Detecting liquid remnants of solid tumors treated with curative intent: Circulating tumor DNA as a biomarker of minimal residual disease (Review)

Oncology Reports, Journal Year: 2023, Volume and Issue: 49(5)

Published: April 12, 2023

Circulating tumor DNA (ctDNA) has emerged as a promising biomarker of minimal residual disease (MRD) in solid tumors. There is increasing evidence to suggest that the detection ctDNA following curative‑intent treatments high potential anticipating future relapse various Multiple liquid biopsy technical approaches and commercial platforms, including tumor‑informed tumor‑agnostic assays, have been developed for ctDNA‑based MRD Accurate analysis remains critical challenge due very low concentration peripheral blood samples, particularly cancer patients surgery or treatment. The present review summarizes current key can be used analyze surveillance tumors provides brief update on assays platforms available detection. date supporting types also reviewed. In addition, biological variables considerations pre‑analytical analytical steps associated with are discussed.

Language: Английский

---

Emerging Roles of Circulating Tumor DNA for Increased Precision and Personalization in Radiation Oncology

Seminars in Radiation Oncology, Journal Year: 2023, Volume and Issue: 33(3), P. 262 - 278

Published: June 16, 2023

Language: Английский

---

Shedding Light on the Prognostic and Predictive Value of Circulating Tumor DNA for Management of Patients with Early-Stage Colon Cancer

Technology in Cancer Research & Treatment, Journal Year: 2025, Volume and Issue: 24

Published: Jan. 1, 2025

The management of early-stage colon cancer involves surgical resection the primary tumor with or without chemotherapy, depending on pathological staging. benefit adjuvant chemotherapy for stage II and III is approximately 5% 15%, indicating need optimization risk stratification patient selection. Several studies have revealed that current clinicopathological factors lack precision. Circulating DNA (ctDNA) cell-free originating from cells can be detected even in absence radiologically detectable disease among patients cancer. Recent cohort ctDNA one most significant prognostic cancer, surpassing clinical factors. Prospective also suggest there may a predictive role decision consideration therapy. Currently, randomized trials are enrolling to better define this role. In review article, we recent literature its We elaborate future utility practice unmet research optimize currently available assays.

Language: Английский

---

Immediate postoperative minimal residual disease detection with MAESTRO predicts recurrence and survival in head and neck cancer patients treated with surgery

medRxiv (Cold Spring Harbor Laboratory), Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 28, 2025

Abstract Purpose While circulating tumor DNA (ctDNA) is a promising biomarker for minimal residual disease (MRD) detection in head and neck squamous cell carcinoma (HNSCC), more sensitive assays are needed accurate MRD at clinically-relevant timepoints. Ultrasensitive immediately after surgery could guide adjuvant therapy decisions, but early ctDNA dynamics poorly understood. Experimental Design We applied MAESTRO, whole-genome, tumor-informed, mutation-enrichment sequencing assay, pooled testing format called MAESTRO-Pool, to plasma samples from HNSCC patients collected during surveillance. evaluated whether predict outcomes. Results Among 24 predominantly HPV-independent (95.8%) patients, rapid clearance occurred by the first postoperative sample (1-3 days postoperatively) 9 without an event (recurrence or death). 13/15 with were MRD+ (PPV = 92.9%; NPV 80%) median fraction (TFx) of 54 ppm (range 6-1,177 ppm). In last immediate window, 8/13 10/13 had TFx below 100 ppm, respectively, limit leading commercial assays. Early correlated worse overall survival (HR 8.3; 95% CI: 1.1-66.1; P 0.02) event-free 27.4; 3.5-214.5; < 0.0001) independent high-risk pathology. Conclusions Immediate MAESTRO was predictive recurrence death. Given ultralow TFxs observed, ultrasensitive will be essential reliable timepoints enable personalized decision-making HNSCC.

Language: Английский

---

The Prospectives and Limitations of Liquid Biopsy Utilization for Clinical Practice in Taiwan

The Journal of Liquid Biopsy, Journal Year: 2025, Volume and Issue: 7, P. 100290 - 100290

Published: March 1, 2025

Language: Английский

---

ctDNA can detect minimal residual disease in curative treated non-small cell lung cancer patients using a tumor agnostic approach

Lung Cancer, Journal Year: 2025, Volume and Issue: 203, P. 108528 - 108528

Published: April 6, 2025

Language: Английский

---

ctDNA-based minimal residual disease detection in lung cancer patients treated with curative intended chemoradiotherapy using a clinically transferable approach

Cancer Treatment and Research Communications, Journal Year: 2024, Volume and Issue: 39, P. 100802 - 100802

Published: Jan. 1, 2024

Reliable biomarkers are needed to identify tumor recurrence of non-small cell lung cancer (NSCLC) patients after chemoradiotherapy (CRT) with curative intent. This could improve consolidation therapy progressing patients. However, the approach existing studies has limited transferability clinic. A retrospective analysis 135 plasma samples from 56 inoperable NSCLC who received CRT intent was performed. Plasma collected at baseline, first check-up (average 1.6 months post-RT), and second 4.5 post-RT) were analyzed by deep sequencing a commercially available personalized profiling strategy (CAPP-Seq) using tumor-agnostic approach. Detection circulating DNA (ctDNA) significantly associated higher odds (OR: 5.4 (CI: 1.1–31), Fisher's exact test: p-value = 0.022), shorter recurrence-free survival (RFS) (HR: 4.1 1.7–10); log-rank 9e-04). In contrast, detection ctDNA not 2.7 0.67–12), 0.13) or RFS 1.5 0.67–3.3); 0.32). study demonstrates that can be used minimal residual disease in kit Furthermore, time point collecting sample decisive importance for prognostic value ctDNA. analysed treated Detecting post-treatment linked odds, indicating ctDNA's potential as biomarker identifying treatment Importantly, emphasizes timing accurate results.

Language: Английский

---

Liquid biopsy in triple-negative breast cancer: unlocking the potential of precision oncology

ESMO Open, Journal Year: 2024, Volume and Issue: 9(10), P. 103700 - 103700

Published: Sept. 16, 2024

Language: Английский

---

Proposal of real-world solutions for the implementation of predictive biomarker testing in patients with operable non-small cell lung cancer

Lung Cancer, Journal Year: 2025, Volume and Issue: unknown, P. 108107 - 108107

Published: Jan. 1, 2025

Language: Английский

---